<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DIDANOSINE- didanosineÂ capsule, delayed releaseÂ </strong><br>American Health Packaging<br></p></div>
<h1>Didanosine Delayed-Release Capsules (enteric-coated pellets)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_10f03b27-2c9d-424c-8e74-cef6ddc70c7b"></a><a name="section-1"></a><p></p>
<p class="First">WARNING:</p>
<p>FATAL AND NONFATAL <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">PANCREATITIS</span> HAVE OCCURRED DURING THERAPY WITH DIDANOSINE USED ALSONE OR IN COMBINATION REGIMENS IN BOTH TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS, REGARDLESS OF DEGREE OF <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">IMMUNOSUPPRESSION</span>, DIDANOSINE SHOULD BE SUSPENDED IN PATIENTS WITH SUSPECTED <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">PANCREATITIS</span> AND DISCONTINUED IN PATIENTS WITH CONFIRMED <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">PANCREATITIS</span> (see <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a>). </p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS, INCLUDING FATAL CASES, HAVE BEEN REPORTED WITH THE USE OF NUCLEOSIDE ANALOGUES ALONE OR IN COMBINATION, INCLUDING DIDANOSINE AND OTHER ANTIRETROVIRALS. FATAL <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> HAS BEEN REPORTED IN PREGNANT WOMEN WHO RECEIVED THE COMBINATION OF DIDANSOINE AND STAVUDINE WITH OTHER ANTIRETROVIRAL AGENTS. THE COMBINATION OF DIDANOSINE AND STAVUDINE SHULD BE USED WITH CAUTION DURING PREGNANCY AND IS RECOMMENDED ONLY IF THE POTENTIAL BENEFIT CLEARLY OUTWEIGHS THE POTENTIAL RISK (SEE <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a> AND <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>, <a href="#i4i_pregnancy_id_5fd36593-abaf-4ff2-ae51-81324b02d10b">Pregnancy, Reproduction and Fertility</a>),</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_31f92dc2-9187-4967-be1a-94edd261ac08"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Didanosine delayed-release capsules are an enteric-coated formulation of didanosine, (ddl), a synthetic purine nucleoside analogue active against the Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus (HIV). Didanosine delayed-release capsules, containing enteric-coated pellets, are available for oral administration in the strengths of 200 mg, 250 mg, and 400 mg of didanosine. The inactive ingredients include croscarmellose sodium, hydroxypropyl cellulose, hypromellose, methacrylic acid copolymer dispersion, microcrystalline cellulose, polydextrose, polyethylene glycol, silicon dioxide, sodium hydroxide, talc, titanium dioxide, triacetin and triethyl citrate.The capsule shell contains FD&amp;C blue no.1, gelatin, and titanium dioxide.The 200 mg capsule shell also contains D&amp;C red no. 33, and FD&amp;C yellow no. 6. The 250 mg capsule shell also contains D&amp;C red no. 28. The 400 mg capsule shell also contains D&amp;C red no.33, and FD&amp;C yellow no. 6. The edible imprinting ink contains D&amp;C yellow no. 10 aluminum lake, FD&amp;C blue no. 1 aluminum lake, FD&amp;C blue no. 2 aluminum lake, FD&amp;C red no. 40 aluminum lake, iron oxide, propylene glycol and shellac glaze. </p>
<p>The chemical name for didanosine is 2', 3'-dideoxyinosine. The structural formula is:</p>
<div class="Figure"><img alt="Didanosine structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79d6a5ea-77d3-4547-aa67-1b465141b1f5&amp;name=79d6a5ea-77d3-4547-aa67-1b465141b1f5-01.jpg"></div>
<p>Didanosine is a white crystalline powder with the molecular formula C10H12N4O3 and a molecular weight of 236.2. The aqueous solubility of didanosine at 25Â° C and pH of approximately 6 is 27.3 mg/mL. Didanosine is unstable in acidic solutions. For example, at pH &lt; 3 and 37Â° C, 10% of didanosine decomposes to hypoxanthine in less than 2 minutes. In didanosine delayed-release capsules, an enteric coating is used to protect didanosine from degradation by stomach acid.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_d3f20860-aa21-4993-a2da-aad8a4297e1a"></a><a name="section-2"></a><p></p>
<h1>MICROBIOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_adfdc60a-8500-4586-b379-99c6658705af"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Didanosine is a synthetic nucleoside analogue of the naturally occurring nucleoside deoxyadenosine in which the 3â€™-hydroxyl group is replaced by hydrogen. Intracellularly, didanosine is converted by cellular enzymes to the active metabolite, dideoxyadenosine 5â€™-triphosphate. Dideoxyadenosine 5â€™-triphosphate inhibits the activity of HIV-1 reverse transcriptase both by competing with the natural substrate, deoxyadenosine 5â€™-triphosphate, and by its incorporation into viral DNA causing termination of viral DNA chain elongation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_543df5c2-8da2-400a-b613-a4c77073c751"></a><a name="section-2.2"></a><p></p>
<h2>In Vitro HIV Susceptibility</h2>
<p class="First">The in vitro anti-HIV-1 activity of didanosine was evaluated in a variety of HIV-1 infected lymphoblastic cell lines and monocyte/macrophage cell cultures. The concentration of drug necessary to inhibit viral replication by 50% (EC50) ranged from 2.5 to 10 Î¼M <br>(1 Î¼M=0.24 Î¼g/mL) in lymphoblastic cell lines and 0.01 to 0.1 Î¼M in monocyte/macrophage cell cultures. The relationship between in vitro susceptibility of HIV to didanosine and the inhibition of HIV replication in humans has not bee established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6c0baffd-5a48-4ecf-ba57-3d1ce64e43da"></a><a name="section-2.3"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></span></h2>
<p class="First">HIV-1 isolates with reduced sensitivity to didanosine have been selected in vitro and were also obtained from patients treated with didanosine. Genetic analysis of isolates from didanosine-treated patients showed mutations in the reverse transcriptase gene that resulted in the amino acid substitutions K65R, L74V, and M184V. The L74V substitution was most frequently observed in clinical isolates. Phenotypic analysis of HIV-1 isolates from 60 patients (some with prior zidovudine treatment) receiving 6 to 24 months of didanosine monotherapy showed that isolates from 10 of 60 patients exhibited an average of a 10-fold decrease in susceptibility to didanosine in vitro compared to baseline isolates. Clinical isolates that exhibited a decrease in didanosine susceptibility harbored one or more didanosine-associated mutations. The clinical relevance of genotypic and phenotypic changes associated with didanosine therapy has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2b31c34-40b4-4a0d-b35d-e6e904151218"></a><a name="section-2.4"></a><p></p>
<h2>Cross-Resistance</h2>
<p class="First">HIV-1 isolates from 2 of 39 patients receiving combination therapy for up to 2 years with  zidovudine and didanosine exhibited decreased susceptibility to zidovudine, didanosine, zalcitabine, stavudine, and lamivudine in vitro. These isolates harbored five mutations (A62V, V75I, F77L, F116Y, and Q151M) in the reverse transcriptase gene. The clinical relevance of these observations has not been estabilished. </p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_1e56d9b2-8fa8-4b79-9eb4-d952e63580b2"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c6d25969-5d6c-40ac-a755-9fae592062c6"></a><a name="section-3.1"></a><p></p>
<h2>Animal Toxicology</h2>
<p class="First">Evidence of a dose-limiting skeletal muscle toxicity has been observed in mice and rats (but not in dogs) following long-term (greater than 90 days) dosing with didanosine at doses that were approximately 1.2 to 12 times the estimated human exposure. The relationship of this finding to the potential of didanosine to cause <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> in humans is unclear. However, human <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> has been associated with administration of didanosine and other nucleoside analogues.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7e4c5d4-a8f6-46df-a8f7-6f731505b34d"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The pharmacokinetic parameters of didanosine are summarized in <a href="#id_87087866-d413-418e-96d4-c548dcc64176">Table 1</a>. Didanosine is rapidly absorbed, with peak plasma concentrations generally observed from 0.25 to 1.50 hours following oral dosing with a buffered formulation. Increases in plasma didanosine concentrations were dose proportional over the range of 50 to 400 mg. Steady-state pharmacokinetic parameters did not differ significantly from values obtained after a single dose. Binding of didanosine to plasma proteins in vitro was low (&lt;5%). Based on data from in vitro and animal studies, it is presumed that the metabolism of didanosine in man occurs by the same pathways responsible for the elimination of endogenous purines.</p>
<p>Comparisons of Didanosine Formulations: In didanosine delayed-release capsules, the active ingredient didanosine, is protected against degradation by stomach acid by the use of an enteric coating on the pellets in the capsule. The enteric coating dissolves when the pellets empty into the small intestines, the site of drug absorption. With buffered formulations of didanosine, administration with antacid provides protection from degradation by stomach acid. In healthy volunteers, as well as subjects infected with HIV, the area under the plasma concetration time curve (AUC) is equivalent for didanosine adminstered as the didanosine delayed-release formulation relative to a buffered tablet formulation. The peak plasma concentration (Cmax) of didanosine, administered as didanosine dleayed-release capsules, is reduced approximately 40% relative to didanosine buffered tablets. The time to the peak concentration (Tmax) increases from approximately 0.67 hours for didanosine buffered tablets to 2 hours for didanosine delayed-release capsules.</p>
<p>Effect of Food on Absorption of Didanosine: In the presence of food, the Cmax and AUC for didanosine were reduced by approximately 46% and 19%, respectively, compared to the fasting state. Didanosine should be taken on an empty stomach.</p>
<a name="id_87087866-d413-418e-96d4-c548dcc64176"></a><table width="324">
<caption><span>Table 1: Pharmacokinetics Parameters for Didanosine in Adults</span></caption>
<col width="54.0%">
<col width="34.6%">
<col width="11.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="top">Parameter</td>
<td class="Botrule Rrule" align="center" valign="top">Mean Â± SD</td>
<td class="Botrule Lrule" align="center" valign="top">n</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Oral bioavailibility<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">42Â±12%</td>
<td class="Botrule Lrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Apparent volume of distribution<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.08Â±0.22 L/kg</td>
<td class="Botrule Lrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">CSF-plasma ratio<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">21Â±0.03%</td>
<td class="Botrule Lrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Systemic clearance<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">13Â±1.6 mL/min/kg</td>
<td class="Botrule Lrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Renal clearance<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5.5Â±2.1 mL/min/kg</td>
<td class="Botrule Lrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Elimination half-life<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.5Â±0.4 h</td>
<td class="Botrule Lrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Urinary recovery of didanosine<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">18Â±8%</td>
<td class="Botrule Lrule" align="center" valign="top">6</td>
</tr>
<tr class="Last"><td class="Botrule" align="left" colspan="3" valign="top"><p class="First">CSF = cerebrospinal fluid<br><span class="Sup">a</span>following oral administration of a buffered formulation<br><span class="Sup">b</span>following I.V. administration.<br><span class="Sup">c</span>mean Â± SE.</p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4e3d5cf6-c795-43c9-9c49-aaa0d3893620"></a><a name="section-3.3"></a><p></p>
<h2>Special Populations</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>: It is recommended that the didanosine dose be modified in patients with reduced creatinine clearance and in patients receiving maintenance hemodialysis (see <a href="#i4i_dosage_admin_id_055d46aa-31c2-4214-b1b8-3001c48e832d">DOSAGE AND ADMINISTRATION</a>). Data from two studies using a buffered formulation of didanosine indicated that the apparent oral clearance of didanosine decreased and the terminal elimination half-life increased as creatinine clearance decreased (see <a href="#id_d76ebe9c-9b6d-49a6-b82e-4169474eac2c">Table 2</a>). Following oral administration, didanosine was not detectable in peritoneal dialysate fluid (n=6); recovery in hemodialysate (n=5) ranged from 0.6% to 7.4% of the dose over a 3 to 4 hour dialysis period. The absolute bioavailability of didanosine was not affected in patients requiring dialysis. </p>
<a name="id_d76ebe9c-9b6d-49a6-b82e-4169474eac2c"></a><table border="none" width="466">
<caption><span>Table 2: Mean Â± SD Pharmacokinetic Parameters for Didanosine Following a Single Oral Dose of a Buffered Formulation </span></caption>
<col width="17.6%">
<col width="15.2%">
<col width="14.2%">
<col width="18.9%">
<col width="15.2%">
<col width="18.9%">
<tbody class="Headless">
<tr class="First"><td align="left" colspan="6" valign="top">ND = not determined due to <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>. <br>CLcr = creatinine clearance.<br>CL/F= apparent oral clearance.<br>CLR= renal clearance.</td></tr>
<tr><td align="center" colspan="6" valign="top">Creatinine Clearance (mL/min)</td></tr>
<tr>
<td align="center" valign="top">Parameter</td>
<td align="center" valign="top">â‰¥ 90 <br>n=12</td>
<td align="center" valign="top">60 to 90<br>n=6</td>
<td align="center" valign="top">30 to 59<br>n=6</td>
<td align="center" valign="top">10 to 29<br>n=3</td>
<td align="center" valign="top">Dialysis Patients<br>n=11</td>
</tr>
<tr>
<td align="center" valign="top">Clcr (mL/min)</td>
<td align="center" valign="top">112 Â± 22</td>
<td align="center" valign="top">68 Â± 8</td>
<td align="center" valign="top">46 Â± 8</td>
<td align="center" valign="top">13 Â± 5</td>
<td align="center" valign="top">ND</td>
</tr>
<tr>
<td align="center" valign="top">CL/F (mL/min)</td>
<td align="center" valign="top">2164 Â± 638</td>
<td align="center" valign="top">1566 Â± 833</td>
<td align="center" valign="top">1023 Â± 378</td>
<td align="center" valign="top">628 Â± 104</td>
<td align="center" valign="top">543 Â± 174</td>
</tr>
<tr>
<td align="center" valign="top">CLR (mL/min)</td>
<td align="center" valign="top">458 Â± 164</td>
<td align="center" valign="top">247 Â± 153</td>
<td align="center" valign="top">100 Â± 44</td>
<td align="center" valign="top">20 Â± 8</td>
<td align="center" valign="top">&lt;10</td>
</tr>
<tr class="Last">
<td align="center" valign="top">T1/2 (h)</td>
<td align="center" valign="top">1.42 Â± 0.33</td>
<td align="center" valign="top">1.59 Â± 0.13</td>
<td align="center" valign="top">1.75 Â± 0.43</td>
<td align="center" valign="top">2 Â± 0.3</td>
<td align="center" valign="top">4.1 Â± 1.2</td>
</tr>
</tbody>
</table>
<p>Pediatric Patients: The pharmacokinetics of didanosine administered as didanosine delayed-release capsules have not been studied in pediatric patients.</p>
<p>Geriatric Patients: Didanosine pharmacokinetics have not been studied in patients over 65 years of age (see <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>, <a href="#i4i_geriatric_use_id_672e0093-19ed-4ea4-842f-1ba71b3423b5">Geriatric use</a>).</p>
<p>Gender: The effects of gender on didanosine pharmacokinetics have not been studied.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_1c08786b-8f64-4c54-88b2-6a989b6792c4"></a><a name="section-3.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">(See also <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>, <a href="#i4i_drug_interaction_id_1c08786b-8f64-4c54-88b2-6a989b6792c4">Drug Interactions</a>.)</p>
<p>Ribavirin has been shown in vitro to increase intracellular triphosphate levels of didanosine, which could cause or worsen clinical toxicities (see <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>, <a href="#i4i_drug_interaction_id_1c08786b-8f64-4c54-88b2-6a989b6792c4">Drug Interactions</a>).</p>
<p>Didanosine Delayed-Release Capsules: <a href="#id_e0e9e975-8ccd-459c-a200-876e00d5b0cd">Table 3</a> and <a href="#id_8d1591df-55d3-4f1e-af29-015921ee0d31"> 4</a>  summarize the effects on AUC and Cmax, with a 90% confidence interval (CI) when available, following coadministration of didanosine delayed-release capsules with a variety of drugs. Clinical recommendations based on drug interaction studies for drugs in bold font are included in <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>, <a href="#i4i_drug_interaction_id_1c08786b-8f64-4c54-88b2-6a989b6792c4">Drug Interactions</a> and <a href="#i4i_dosage_admin_id_055d46aa-31c2-4214-b1b8-3001c48e832d">DOSAGE AND ADMINISTRATION</a>.</p>
<p>Â </p>
<a name="id_e0e9e975-8ccd-459c-a200-876e00d5b0cd"></a><table width="445">
<caption><span>Table 3: Results of Drug Interaction Studies with Didanosine Delayed-Release Capsules: Effects of Coadministered Drug on Didanosine Plasma AUC and Cmax Values<span class="Sup">a</span></span></caption>
<col width="19.3%">
<col width="22.7%">
<col width="7.4%">
<col width="23.4%">
<col width="27.2%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="top">Drug</td>
<td class="Botrule Rrule" align="center" valign="top">Didanosine Dosage</td>
<td class="Botrule Rrule" align="center" valign="top">n</td>
<td class="Botrule Rrule" align="center" valign="top">AUC of Didanosine (90% CI)</td>
<td class="Botrule Lrule" align="center" valign="top">Cmax of Didanosine (90% CI)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">tenofovir</span>,<span class="Sup">b</span></p>
<p>300 mg once daily with a light meal<span class="Sup">c</span></p>
</td>
<td class="Botrule Rrule" align="left" valign="top">400 mg single dose fasting 2 h before tenofovir</td>
<td class="Botrule Rrule" align="center" valign="top">26</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘ 48%<br>(31, 67%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">â†‘ 48%<br>(25, 76%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">tenofovir</span>,<span class="Sup">b</span></p>
<p>Â 300 mg once daily with a light meal<span class="Sup">c</span></p>
</td>
<td class="Botrule Rrule" align="left" valign="top">400 mg single dose with tenofovir and a light meal</td>
<td class="Botrule Rrule" align="center" valign="top">25</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†‘ 60% <br>(44, 79%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">â†‘ 64% <br>(41, 89%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">tenofovir</span>,<span class="Sup">b</span></p>
<p>Â 300 mg once daily with a light meal<span class="Sup">c</span></p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">200 mg single dose with tenofovir and a light meal</p>
<p>250 mg single dose with tenogovir and a light meal</p>
<p>325 mg single dose with tenofovir and a light meal</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">33</p>
<p>33</p>
<p>33</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">â†‘ 16%<br>(6, 27%)<span class="Sup">d</span></p>
<p>â†”(-13, 5%)<span class="Sup">e</span></p>
<p>Â </p>
<p>Â â†‘ 13%</p>
<p>(3, 24%)</p>
</td>
<td class="Botrule Lrule" align="left" valign="top">
<p class="First">â†“ 12%<br>(-25, 3%)<span class="Sup">d</span></p>
<p>â†“ 20%<br>(-32, -7%)<span class="Sup">e</span></p>
<p>â†“ 11%<br>(-24, 4%)<span class="Sup">e</span></p>
</td>
</tr>
<tr class="Last"><td class="Botrule" align="left" colspan="5" valign="top">
<p class="First">â†‘ indicates increase.</p>
<p>â†“ indicates decrease.</p>
<p>â†” indicates no change, or mean increase or decrease of &lt;10%.</p>
<p><span class="Sup">a</span> All studies conducted in healthy volunteers â‰¥60kg with creatinine clearance â‰¥60  <br>                mL/min.<br><span class="Sup">b</span> tenofovir disporoxil fumarate.<br><span class="Sup">c</span> 373 kcalories, 8.2 grams fat.<br><span class="Sup">d</span> Compared with didanosine delayed-release capsules 250 mg administered alone under <br>                fasting coniditions.<br><span class="Sup">e</span> Compared with didanosine delayed-release capsules 400 mg administered alone under </p>
<p>                fasting conditions.</p>
</td></tr>
</tbody>
</table>
<a name="id_8d1591df-55d3-4f1e-af29-015921ee0d31"></a><table border="none" width="559">
<caption><span>Table 4: Results of Drug Interaction Studies with Didanosine Delayed-Release Capsules: Effects of Didanosine on Coadministered Drug Plasma AUC and Cmax Values<span class="Sup">a</span></span></caption>
<col width="36.1%">
<col width="24.7%">
<col width="10.7%">
<col width="18.6%">
<col width="9.8%">
<tbody class="Headless">
<tr class="First"><td align="left" colspan="5" valign="top">â†” Indicates no change, or mean increase or decrease of less than 10%. </td></tr>
<tr><td align="left" colspan="5" valign="middle">
<p class="First"><a href="http://C:%5CDocuments%20and%20Settings%5Cmryman%5CLocal%20Settings%5CTemp%5C22e2ca82-c7b5-4f03-9a81-81e130237565.xml">*</a> The 90% confidence intervals for the percent change in the pharmacokinetic parameter are displayed. </p>
<p><a href="http://C:%5CDocuments%20and%20Settings%5Cmryman%5CLocal%20Settings%5CTemp%5C22e2ca82-c7b5-4f03-9a81-81e130237565.xml">â€ </a> All studies conducted in healthy volunteers â‰¥ 60 kg with creatinine clearance â‰¥ 60 mL/min.</p>
<p><a href="http://C:%5CDocuments%20and%20Settings%5Cmryman%5CLocal%20Settings%5CTemp%5C22e2ca82-c7b5-4f03-9a81-81e130237565.xml">â€¡</a> Tenofovir disoproxil fumarate.</p>
<p><a href="http://C:%5CDocuments%20and%20Settings%5Cmryman%5CLocal%20Settings%5CTemp%5C22e2ca82-c7b5-4f03-9a81-81e130237565.xml">Â§</a> 373 kcalories, 8.2 grams fat.</p>
</td></tr>
<tr>
<td align="center" valign="top">
<p class="First">Â  </p>
<p>Â  </p>Drug </td>
<td align="center" valign="top"><p class="First">Didanosine Dosage  </p></td>
<td align="center" valign="top"><p class="First">n</p></td>
<td align="center" valign="top"><p class="First">AUC of Coadministered Drug</p></td>
<td align="center" valign="top"><p class="First">Cmax of Coadministered Drug</p></td>
</tr>
<tr class="Last">
<td align="left" valign="top">
<p class="First">ciprofloxacin, <br>750 mg single dose</p>
<p>indinavir,<br>800 mg single dose</p>
<p>ketoconazole, <br>200 mg single dose</p>
<p>tenofovir,<a href="http://C:%5CDocuments%20and%20Settings%5Cmryman%5CLocal%20Settings%5CTemp%5C22e2ca82-c7b5-4f03-9a81-81e130237565.xml">â€¡</a><br>300 mg once daily<br>with a light meal<a href="http://C:%5CDocuments%20and%20Settings%5Cmryman%5CLocal%20Settings%5CTemp%5C22e2ca82-c7b5-4f03-9a81-81e130237565.xml">Â§</a></p>
<p>tenofovir,<a href="http://C:%5CDocuments%20and%20Settings%5Cmryman%5CLocal%20Settings%5CTemp%5C22e2ca82-c7b5-4f03-9a81-81e130237565.xml">â€¡</a><br>300 mg once daily<br> with a light meal<a href="http://C:%5CDocuments%20and%20Settings%5Cmryman%5CLocal%20Settings%5CTemp%5C22e2ca82-c7b5-4f03-9a81-81e130237565.xml">Â§</a></p>
<p><a href="http://C:%5CDocuments%20and%20Settings%5Cmryman%5CLocal%20Settings%5CTemp%5C22e2ca82-c7b5-4f03-9a81-81e130237565.xml"></a></p>
</td>
<td align="center" valign="top">
<p class="First">400 mg single dose</p>
<p>400 mg single dose</p>
<p>400 mg single dose</p>
<p>400 mg single dose</p>
<p>fasting 2h before</p>
<p>tenofovir</p>
<p>400 mg single dose</p>
<p>with tenofovir and</p>a light meal</td>
<td align="center" valign="top">
<p class="First">16</p>
<p>23</p>
<p>21</p>
<p>25</p>
<p>25</p>
</td>
<td align="center" valign="top">
<p class="First">â†”</p>
<p>â†”</p>
<p>â†”</p>
<p>â†”</p>
<p>â†”</p>
</td>
<td align="center" valign="top">
<p class="First">â†”</p>
<p>â†”</p>
<p>â†”</p>
<p>â†”</p>
<p>â†”</p>
</td>
</tr>
</tbody>
</table>
<p>Didanosine Buffered Formulations: <a href="#id_29417304-bcff-441c-9751-0ac37671a977">Table 5</a>and <a href="#id_d62f2605-5805-456c-a77f-cc8af2ed3224">6 </a> summarize the effects on AUC and Cmax, with a 90% or 95% CI when available, following coadministration of buffered formulations of didanosine with a variety of drugs. Except as noted in table footnotes, the results of these studies may be expected to apply to didanosine. For most of the listed drugs, no clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were noted. Clinical recommendations based on drug interaction studies for drugs in bold font are included in <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>, <a href="#i4i_drug_interaction_id_1c08786b-8f64-4c54-88b2-6a989b6792c4">Drug Interactions</a> and <a href="#i4i_dosage_admin_id_055d46aa-31c2-4214-b1b8-3001c48e832d">DOSAGE AND ADMINISTRATION</a> (for tenofovir).</p>
<a name="id_29417304-bcff-441c-9751-0ac37671a977"></a><table width="559">
<caption><span>Table 5: Results of Drug Interaction Studies with Buggered Formulations of Didanosine: Effects of Coadministered Drug on Didanosine plasma AUC and Cmax Values</span></caption>
<col width="22.5%">
<col width="21.6%">
<col width="10.7%">
<col width="18.6%">
<col width="26.5%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule" align="left" colspan="5" valign="top"><span class="Bold"><span class="Italics">Drugs With Clinical Recommendations Regarding Coadministration (see <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>, <a href="#i4i_section_id_d91d9f86-90ea-4ab6-b400-745b349d7afa">Drug Interactions</a> )</span></span></td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Drug</td>
<td class="Botrule Rrule" align="left" valign="top">Didanosine Dosage</td>
<td class="Botrule Rrule" align="left" valign="top">n</td>
<td class="Botrule Rrule" align="left" valign="top">AUC Didanosine (95% CI)</td>
<td class="Botrule Lrule" align="left" valign="top">Cmax of Didanosine (95% CI)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">allopurinol</span>,</p>
<p>Renally impaired, 300 mg/day</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">200 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">2</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘312%</td>
<td class="Botrule Lrule" align="left" valign="top">â†‘232%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">healthy volunteer, 300 mg/day for 7 days</td>
<td class="Botrule Rrule" align="left" valign="top">400 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">14</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘113%</td>
<td class="Botrule Lrule" align="left" valign="top">â†‘69%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold">ganciclovir</span>, 1000 mg q8h, 2 h after didanosine</td>
<td class="Botrule Rrule" align="left" valign="top">200 mg q12h</td>
<td class="Botrule Rrule" align="left" valign="top">12</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘111%</td>
<td class="Botrule Lrule" align="left" valign="top">NA</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold">methadone</span>, chronic maintenance dose</td>
<td class="Botrule Rrule" align="left" valign="top">200 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">16, 10<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">â†“57%</td>
<td class="Botrule Lrule" align="left" valign="top">â†“66%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold">tenofovir</span>,<span class="Sup">b</span> 300 mg once daily 1 h after didanosine</td>
<td class="Botrule Rrule" align="left" valign="top">250<span class="Sup">c</span> or 400 mg once daily for 7 days</td>
<td class="Botrule Rrule" align="left" valign="top">14</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘44% (31, 59%)<span class="Sup">d</span>
</td>
<td class="Botrule Lrule" align="left" valign="top">â†”28% (11, 48%)<span class="Sup">d</span>
</td>
</tr>
<tr><td class="Botrule Lrule" align="left" colspan="5" valign="top"><span class="Bold">No Clinically Significant Interactions Observed</span></td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">ciprofloxacin, 750 mg q12h for 3 days, 2 h before didanosine</td>
<td class="Botrule Rrule" align="left" valign="top">200 mg q12h for 3 days</td>
<td class="Botrule Rrule" align="left" valign="top">8<span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">â†“16%</td>
<td class="Botrule Lrule" align="left" valign="top">â†“28%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">ininavir, 800 mg single dose simultaneous</td>
<td class="Botrule Rrule" align="left" valign="top">200 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">16</td>
<td class="Botrule Rrule" align="left" valign="top"><p class="First">â†”</p></td>
<td class="Botrule Lrule" align="left" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">1 h before didanosine</td>
<td class="Botrule Rrule" align="left" valign="top">200 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">16</td>
<td class="Botrule Rrule" align="left" valign="top">â†“17% (-27, -7%)<span class="Sup">d</span>
</td>
<td class="Botrule Lrule" align="left" valign="top">â†“13% (-28, 5%)<span class="Sup">d</span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">ketoconazole, 200 mg/day for 4 days, 2 h before didanosine</td>
<td class="Botrule Rrule" align="left" valign="top">375 mg q12h for 4 days</td>
<td class="Botrule Rrule" align="left" valign="top">12<span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">â†”</td>
<td class="Botrule Lrule" align="left" valign="top">â†“12%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">loperamide, 4 mg q6h for 1 day</td>
<td class="Botrule Rrule" align="left" valign="top">300 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">12<span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">â†”</td>
<td class="Botrule Lrule" align="left" valign="top">â†“23%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">metoclopramide, 10 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">300 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">12<span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">â†”</td>
<td class="Botrule Lrule" align="left" valign="top">â†‘13%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">ranitidine, 150 mg 2 h before didansine</td>
<td class="Botrule Rrule" align="left" valign="top">375 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">12<span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘14%</td>
<td class="Botrule Lrule" align="left" valign="top">â†‘13%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">rifabutin, 300 or 600 mg/day for 12 days</td>
<td class="Botrule Rrule" align="left" valign="top">167 or 250 mg q12h for 12 days</td>
<td class="Botrule Rrule" align="left" valign="top">11</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘13% (-1, 27%)</td>
<td class="Botrule Lrule" align="left" valign="top">â†‘17% (-4, 38%)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">ritonavir, 600 mg q12h for 4 days</td>
<td class="Botrule Rrule" align="left" valign="top">200 mg q12h for 4 days</td>
<td class="Botrule Rrule" align="left" valign="top">12</td>
<td class="Botrule Rrule" align="left" valign="top">â†“13% (0, 23%)</td>
<td class="Botrule Lrule" align="left" valign="top">â†“16% (5, 26%)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">stavudine, 40 mg q12h for 4 days</td>
<td class="Botrule Rrule" align="left" valign="top">100 mg q12h for 4 days</td>
<td class="Botrule Rrule" align="left" valign="top">10</td>
<td class="Botrule Rrule" align="left" valign="top">â†”</td>
<td class="Botrule Lrule" align="left" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">sulfamethoxazole, 1000 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">200 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">8<span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">â†”</td>
<td class="Botrule Lrule" align="left" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">trimethoprim, 200 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">200 mg single dose</td>
<td class="Botrule Rrule" align="left" valign="top">8<span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">â†”</td>
<td class="Botrule Lrule" align="left" valign="top">â†‘17% (-23, 77%)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">zidovudine, 200 mg q7h for 3 days</td>
<td class="Botrule Rrule" align="left" valign="top"> 200 mg q12h for 3 days</td>
<td class="Botrule Rrule" align="left" valign="top">8<span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">â†”</td>
<td class="Botrule Lrule" align="left" valign="top">â†”</td>
</tr>
<tr class="Last"><td class="Botrule" align="left" colspan="5" valign="top">
<p class="First">â†‘ indicates increase<br>â†“ indicates decrease<br>â†” indicates no change, or mean increase or decrease of &lt;10%.<br><span class="Sup">a</span> Parellel-group design; entries are subjects receiving combination and control regimens, respectively.<br><span class="Sup">b</span> tenogovir disoproxil fumarate<br><span class="Sup">c</span> patients &lt;60 kg with creatinine clearance &gt;60 mL/min.</p>
<p><span class="Sup">d</span> 90% CI<br><span class="Sup">e</span> HIV-infected patients<br>N/A Not available</p>
</td></tr>
</tbody>
</table>
<a name="id_d62f2605-5805-456c-a77f-cc8af2ed3224"></a><table width="494">
<caption><span>Table 6: Results of Drug Interaction Studies with Buffered Formulations of Didanosine: Effects of Didanosine on Coadministered Drug Plasma AUC and Cmax Values</span></caption>
<col width="25.5%">
<col width="17.8%">
<col width="9.9%">
<col width="22.3%">
<col width="24.5%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule" align="left" colspan="5" valign="top">No Clinically Significant Interaction Observed</td></tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">Drug</td>
<td class="Botrule Rrule" align="center" valign="top">Didanosine Dosage</td>
<td class="Botrule Rrule" align="center" valign="top">n</td>
<td class="Botrule Rrule" align="center" valign="top">AUC of Coadministered Drug (95% CI)</td>
<td class="Botrule Lrule" align="center" valign="top">Cmax of Coadministered Drug (95% CI)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">dapsone, 100 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">200 mg q12h for 14 days</td>
<td class="Botrule Rrule" align="center" valign="top">6<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Lrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">delaviridine, 400 mg single dose simultaneous</td>
<td class="Botrule Rrule" align="center" valign="top">125 or 200 mg q12h</td>
<td class="Botrule Rrule" align="center" valign="top">12<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“32%<span class="Sup">b</span>
</td>
<td class="Botrule Lrule" align="center" valign="top">â†“53%<span class="Sup">b</span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">1 hr before didanosine</td>
<td class="Botrule Rrule" align="center" valign="top">125 or 200 mg q12h</td>
<td class="Botrule Rrule" align="center" valign="top">12<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘20%</td>
<td class="Botrule Lrule" align="center" valign="top">â†‘18%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">ganciclovir, 1000 mg q8h, 2h after didanosine</td>
<td class="Botrule Rrule" align="center" valign="top">200 mg q12h</td>
<td class="Botrule Rrule" align="center" valign="top">12<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“21%</td>
<td class="Botrule Lrule" align="center" valign="top">NA</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">nelfinavir, 750 mg single dose, 1 h after didanosine</td>
<td class="Botrule Rrule" align="center" valign="top">200 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">10<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘12%</td>
<td class="Botrule Lrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">ranitidine, 150 mg single dose, 2 h before didanosine</td>
<td class="Botrule Rrule" align="center" valign="top">375 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">12<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“16%</td>
<td class="Botrule Lrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">ritonavir, 600 mg q12h for 4 days</td>
<td class="Botrule Rrule" align="center" valign="top">200 mg q12h for 4 days</td>
<td class="Botrule Rrule" align="center" valign="top">12Â </td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Lrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">stavudine, 40 mg q12h for 4 days</td>
<td class="Botrule Rrule" align="center" valign="top">100 mg q12h for 4 days</td>
<td class="Botrule Rrule" align="center" valign="top">10<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Lrule" align="center" valign="top">â†‘17%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">sulfamethoxazole, 1000 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">200 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">8<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“11% (-17, -4%)</td>
<td class="Botrule Lrule" align="center" valign="top">â†“12% (-28, 8%)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">tenofovir,<span class="Sup">C</span> 300 mg once daily 1 h after didanosine</td>
<td class="Botrule Rrule" align="center" valign="top">250<span class="Sup">d</span> or 400 mg once daily for 7 days</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Lrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">trimethoprim, 200 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">200 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">8<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘10% (-9, 34%)</td>
<td class="Botrule Lrule" align="center" valign="top">â†“22% (-59, 49%)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">zidovudine, 200 mg q8h for 3 days</td>
<td class="Botrule Rrule" align="center" valign="top">200 mg q12h for 3 days</td>
<td class="Botrule Rrule" align="center" valign="top">6<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“10% (-27, 11%)</td>
<td class="Botrule Lrule" align="center" valign="top">â†“16.5% (-53, 47%)</td>
</tr>
<tr class="Last"><td class="Botrule" align="left" colspan="5" valign="top">
<p class="First">â†‘ indicates increase.</p>
<p>â†“indicates decrease.</p>
<p>â†” indicates no change, or mean increase or decrease of &lt;10%.<br><span class="Sup">a</span>HIV-infected patients.<br><span class="Sup">b</span>This result is probably related to the bugger and is not expected to occur with didanosine delayed-release capsules.<br><span class="Sup">c</span>tenofovir disoproxil fumarate.<br><span class="Sup">d</span>patients &lt;60 kg with creatinine clearance &gt;60 mL/min.</p>NA Not available</td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_ec8d9332-4592-47d8-bd16-92841410fc29"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Didanosine delayed-release capsules in combination with other antiretroviral agents is indicated for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults. (See <a href="#i4i_clinical_studies_id_026b9627-7e4c-4bba-9e6a-9ca32ae5a08f">Clinical Studies</a>.)</p>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_026b9627-7e4c-4bba-9e6a-9ca32ae5a08f"></a><a name="section-4.1"></a><p></p>
<h2>Clinical Studies</h2>
<p class="First">Study AI454-152 was a 48-week, randomized, open-label study comparing didanosine (400 mg once daily) plus stavudine (40 mg twice daily) plus nelfinavir (750 mg three times daily) to zidovudine (300 mg) plus lamivudine (150 mg) combination tablets twice daily plus nelfinavir (750 mg three times daily) in 511 treatment-naive patients, with a mean CD4 cell count of 411 cells/mm3(range 39 to 1105 cells/mm3) and a mean plasma HIV-1 RNA of 4.71 log10 copies/mL (range 2.8 to 5.9 log10 copies/mL) at baseline. Patients were primarily males (72%) and Caucasian (53%) with a mean age of 35 years (range 18 to 73 years). The percentages of patients with HIV-1 RNA &lt;400 and &lt;50 copies/mL and outcomes of patients through 48 weeks are summarized in <a href="#id_33cff1dc-aa0e-4c59-abae-1ca90d5a76c0">Figure 1</a> and <a href="#id_df83a925-2366-4e01-b7e8-66c5465854ca">Table 7</a>, respectively.</p>
<div class="Figure">
<img alt="Treatment Response Through week 48* chart" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79d6a5ea-77d3-4547-aa67-1b465141b1f5&amp;name=79d6a5ea-77d3-4547-aa67-1b465141b1f5-02.jpg"><p class="MultiMediaCaption">Figure 1 Treatment Response Through Week 48*, AI454-152</p>
</div>
<p><span class="Bold">â—‹â—? didanosine + stavudine + nelfinavir, n= 258</span></p>
<p><span class="Bold">âˆ†â–² zidovudine/lamivudine + nelfinavir, n= 253</span></p>
<p>*Percent of patients at each time point who have HIV RNA &lt;400 or &lt;50 copies/mL and do not meet any criteria for treatment failure (eg, virologic failure or discontinuation for any reason).</p>
<a name="id_df83a925-2366-4e01-b7e8-66c5465854ca"></a><table width="0.000">
<caption><span>Table 7: Outcomes of Randomized Treatment Through Week 48, AI454-152</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Lrule" align="left" colspan="2" valign="top">Percent of Patients with HIV RNA &lt;400 copies/mL (&lt;50 copies/mL)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Outcome</td>
<td class="Botrule Rrule" align="center" valign="top">didanosine+<br> stavudine+<br> nelfinavir<br>n=258</td>
<td class="Botrule Lrule" align="center" valign="top">zidovudine/<br>lamivudine<span class="Sup">a</span>+<br>nelfinavir<br>n=253</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Responder<span class="Sup">b, c</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">55% (33%)</td>
<td class="Botrule Lrule" align="left" valign="top">56% (33%)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Virologic failure<span class="Sup">d</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">22% (45%)</td>
<td class="Botrule Lrule" align="left" valign="top">21% (43%)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or discontinued due to disease progression</td>
<td class="Botrule Rrule" align="left" valign="top">1% (1%)</td>
<td class="Botrule Lrule" align="left" valign="top">2% (2%)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Discontinued due to adverse event</td>
<td class="Botrule Rrule" align="left" valign="top">6% (6%)</td>
<td class="Botrule Lrule" align="left" valign="top">7% (7%)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Discontinued due to other reasons<span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">16% (16%)</td>
<td class="Botrule Lrule" align="left" valign="top">15% (16%)</td>
</tr>
<tr class="Last"><td class="Botrule" align="left" colspan="3" valign="top">
<span class="Sup">a</span>Zidovudine/lamivudine combination tablet.<br><span class="Sup">b</span>Corresponds to rates at Week 48 in Figure 1.s decision, never treated, and other reasons.<br><span class="Sup">c</span>Subjects achieved and maintained confirmed HIV RNA &lt;400 copies/mL (&lt;50 copies/mL)<br><span class="Sup">d</span>Includes viral rebound at or before Week 48 and failure to achieve confirmed HIV RNA &lt;400 copies/mL (&lt;50 copies/mL) through Week 48.<br><span class="Sup">e</span>Includes lost to follow-up, subject's withdrawal, discontinuation due to physician</td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_e3837b5e-797e-4c76-bef6-5eadb1dadc71"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Didanosine delayed-release capsules are contraindicated in patients with previously demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of the formulation.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_631d91a4-0d32-4b91-a6ab-cdcc7123b236"></a><a name="section-6.1"></a><p></p>
<h2>1. <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>:</h2>
<p class="First"><span class="Bold">    FATAL AND NONFATAL <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">PANCREATITIS</span> HAVE OCCURRED DURING THERAPY WITH DIDANOSINE USED ALONE OR IN COMBINATION REGIMENS IN BOTH TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS, REGARDLESS OF DEGREE OF <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">IMMUNOSUPPRESSION</span>. DIDANOSINE SHOULD BE SUSPENDED IN PATIENTS WITH SIGNS OR SYMPTOMS OF <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">PANCREATITIS</span> AND DISCONTINUED IN PATIENTS WITH CONFIRMED <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">PANCREATITIS</span>. PATIENTS TREATED WITH DIDANOSINE IN COMBINATION WITH STAVUDINE, WITH OR WITHOUT HYDROXYUREA, MAY BE AT INCREASED RISK FOR <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">PANCREATITIS</span>.</span></p>
<p>When treatment with life-sustaining drugs known to cause pancreatic toxicity is required, suspension of didanosine therapy is recommended. In patients with risk factors for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, didanosine should be used with extreme caution and only if clearly indicated. Patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, especially the elderly, are at increased risk of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and should be followed closely. Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> may be at greater risk for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> if treated without dose adjustment. The frequency of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is dose related. In phase 3 studies with buffered formulations of didanosine, incidence ranged from 1% to 10% with doses higher than are currently recommended and 1% to 7% with recommended dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bb9c0477-3117-412d-9c84-62e9b8d292a8"></a><a name="section-6.2"></a><p></p>
<h2>2. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis:</h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including didanosine and other antiretrovirals. </span>A majority of these cases have been in women. <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> and prolonged nucleoside exposure may be risk factors. Fatal <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents. The combination of didanosine and stavudine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk (see <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>, <a href="#i4i_pregnancy_id_5fd36593-abaf-4ff2-ae51-81324b02d10b">Pregnancy, Reproduction and Fertility</a>). Particular caution should be exercised when administering didanosine to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with didanosine should be suspended in any patient who develops clinical or laboratory findings suggestive of symptomatic hyperlactatemia, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_12a7e679-80d7-4953-a631-d46c730b0b65"></a><a name="section-6.3"></a><p></p>
<h2>3. Retinal Changes and Optic NeuritisÂ  </h2>
<p class="First">Retinal changes and <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> have been reported in patients taking didanosine. Periodic retinal examinations should be considered for patients receiving didanosine (see <a href="#i4i_adverse_effects_id_ed8c3f9a-4fe6-4ad2-85f6-7e38d77f0406">ADVERSE REACTIONS</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e18e03ae-b510-4b77-ac04-1ba6153dd6a7"></a><a name="section-7.1"></a><p></p>
<h2>Dosing:</h2>
<p class="First">Didanosine should be administered once daily on an empty stomach.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_575a865e-36d3-4ecd-898f-1b1103274e75"></a><a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span>:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, manifested by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the hands or feet, has been reported in patients receiving didanosine therapy. <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> has occurred more frequently in patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>, in patients with a history of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, or in patients being treated with neurotoxic drug therapy, including stavudine (see <a href="#i4i_adverse_effects_id_ed8c3f9a-4fe6-4ad2-85f6-7e38d77f0406">ADVERSE REACTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_20df593d-a4cd-4266-accb-33217129e470"></a><a name="section-7.3"></a><p></p>
<h2>Fat Redistribution:</h2>
<p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and "cushiongoid appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_fd840a60-f524-4877-acce-d8307f6741a7"></a><a name="section-7.4"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4edfbf3f-4543-4fca-a93c-b07981bb7bee"></a><a name="section-7.4.1"></a><p></p>
<h3>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </h3>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;60 mL/min) may be at greater risk of toxicity from didanosine due to decreased drug clearance (see <a href="#i4i_clinical_pharmacology_id_1e56d9b2-8fa8-4b79-9eb4-d952e63580b2">CLINICAL PHARMACOLOGY</a>). A dose reduction is recommended in these patients (see <a href="#i4i_dosage_admin_id_055d46aa-31c2-4214-b1b8-3001c48e832d">DOSAGE AND ADMINISTRATION</a>).<br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_58cb2db8-73e5-45eb-b520-1e3d96decb5b"></a><a name="section-7.4.2"></a><p></p>
<h3>Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</h3>
<p class="First">It is unknown if <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> significantly affects didanosine pharmacokinetics. Therefore, these patients should be monitored closely for evidence of didanosine toxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a127ff54-ab0a-47d6-95b6-3e7f8585abce"></a><a name="section-7.4.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span>:</h3>
<p class="First">Didanosine has been associated with asymptomatic <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>; treatment suspension may be necessary if clinical measures aimed at reducing uric acid levels fail.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_c58964b7-3835-42dc-bfc5-45c4fd661f1a"></a><a name="section-7.5"></a><p></p>
<h2>Information for patients </h2>
<p class="First">(See Patient Information Leaflet.)</p>
<p>Patients should be informed that a serious toxicity of didanosine, used alone and in combination regimens, is <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, which may be fatal. Patients should also be aware that <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, manifested by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in hands or feet, may develop during therapy with didanosine. Patients should be counseled that <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> occures with greatest frequency in patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> or a history of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, and that dose modification and/or discontinuation of didanosine may be required if toxicity develops. Patients should be informed that when didanosine is used in combination with other agents with similar toxicities, the incidence of adverse events may be higher than when didanosine is used alone. These patients should be followed closely. Patients should be cautioned about the use of medications or other substances, including alcohol, that may exacerbate didanosine toxicities. Didanosine is not cure for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, and patients may continue to develop HIV-associated illnesses, including oppurtunistic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Therefore, patients should remain under the care of a physician when using didanosine. Patients should be advised that didanosine therapy has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination. Patients should be informed that the long-term effects of didanosine are unknown at this time. Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d91d9f86-90ea-4ab6-b400-745b349d7afa"></a><a name="section-7.6"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">(see also <a href="#i4i_clinical_pharmacology_id_1e56d9b2-8fa8-4b79-9eb4-d952e63580b2">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_drug_interaction_id_1c08786b-8f64-4c54-88b2-6a989b6792c4">Drug Interactions</a>):</p>
<p>Drug interactions that have been established based on drug interaction studies are listed with the pharmacokinetic results in <a href="#i4i_clinical_pharmacology_id_1e56d9b2-8fa8-4b79-9eb4-d952e63580b2">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_drug_interaction_id_1c08786b-8f64-4c54-88b2-6a989b6792c4">Drug Interactions</a> (<a href="#id_e0e9e975-8ccd-459c-a200-876e00d5b0cd">Tables 3</a> and <a href="#id_d62f2605-5805-456c-a77f-cc8af2ed3224">6</a> ). The clinical recommendatins based on the results of these studies are listed in <a href="#id_07c938a8-f6f0-4f2a-b348-49271d77d470">Table 8</a>.</p>
<a name="id_07c938a8-f6f0-4f2a-b348-49271d77d470"></a><table width="478">
<caption><span>Table 8: Established Drug Interactions Based on Studies with Didanosine Delayed-Release Capsules or Studies with Buffered Formulations of Didanosine and Expected to Occur with Didanosine Delayed-Release Capsules</span></caption>
<col width="13.8%">
<col width="24.1%">
<col width="62.1%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule" align="left" colspan="3" valign="top">Coadministration Not Recommended Based on Drug Interaction Studies (see <a href="#i4i_clinical_pharmacology_id_1e56d9b2-8fa8-4b79-9eb4-d952e63580b2">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_section_id_d91d9f86-90ea-4ab6-b400-745b349d7afa">Drug Interactions</a> for Magnitude of Interaction)</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Drug</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Effect</span></td>
<td class="Botrule Lrule" align="left" valign="top"><span class="Bold">Clinical Comment</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">allopurinol</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘didanosine concentration</td>
<td class="Botrule Lrule" align="left" valign="top">Coadministration not recommended</td>
</tr>
<tr><td class="Botrule Lrule" align="left" colspan="3" valign="top">Alteration in Dose or Regimen Recommended Based on Drug Interaction Studies (see <a href="#i4i_clinical_pharmacology_id_1e56d9b2-8fa8-4b79-9eb4-d952e63580b2">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_drug_interaction_id_1c08786b-8f64-4c54-88b2-6a989b6792c4">Drug Interactions</a> for Magnitude of Interaction</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Drug</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Effect</span></td>
<td class="Botrule Lrule" align="left" valign="top"><span class="Bold">Clinical Comment</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">ganciclovir</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘didanosine concentration</td>
<td class="Botrule Lrule" align="left" valign="top">Appropriate doses for this combination, with respect to efficacy and safety, have not been established</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">methadone</td>
<td class="Botrule Rrule" align="left" valign="top">â†“didanosine concentration</td>
<td class="Botrule Lrule" align="left" valign="top">Appropriate doses for this combination, with respect to efficacy and safety, have not been established</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">tenofovir disoproxil fumarate</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘didanosine concentration</td>
<td class="Botrule Lrule" align="left" valign="top">A dose reduction of Didanosine Delayed-Release Capsules to 250 mg (adults weighing â‰¥60 kg with creatinine clearance â‰¥60 mL/min) or 200 mg (adults weighing &lt;60 kg with creatinine clearance â‰¥60 mL/min) once daily taken together with tenofovir and a light meal (â‰¤400 kcalories and â‰¤20% fat) or in the fasted state is recommended. Patients should be monitored for didanosine-associated toxicities (see <a href="#i4i_section_id_8103d773-cb22-4089-8fe0-3e25f78aaaaf">below</a>).</td>
</tr>
<tr class="Last"><td class="Botrule" align="left" colspan="3" valign="top">â†‘ indicates increase â†“ indicates decrease</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8103d773-cb22-4089-8fe0-3e25f78aaaaf"></a><a name="section-7.7"></a><p></p>
<h2>Coadministration of didanosine with drugs that are known to cause <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> may increase the risk of this toxicity<span class="Bold"> (see </span>WARNINGS, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>). Predicted drug interactions with didanosine are listed in Table 9.</h2>
<a name="id_fd1a7a28-da3c-4b56-a6ce-7581f537a42f"></a><table width="478">
<caption><span>Table 9: Predicted Drug Interactions with Didanosine Delayed-Release Capsules</span></caption>
<col width="30.1%">
<col width="30.1%">
<col width="39.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Drug or Drug Class</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Effect</span></td>
<td class="Botrule Lrule" align="left" valign="top"><span class="Bold">Clinical Comment</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Drugs that may cause pancreatic toxicity</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘risk of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></td>
<td class="Botrule Lrule" align="left" valign="top">Use only with extreme caution.<span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Neurotoxic drugs</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘risk of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span></td>
<td class="Botrule Lrule" align="left" valign="top">Use with caution.<span class="Sup">b</span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Ribavirin</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘risk of toxicity</td>
<td class="Botrule Lrule" align="left" valign="top">Ribavirin has been shown in vitro to increase intracellular triphosphate levels of didanosine. Coadministration is not recommended (see <a href="#i4i_section_id_9176c7c8-8251-4325-97a7-b2eadcffab21">below</a>)</td>
</tr>
<tr class="Last"><td class="Botrule" align="left" colspan="3" valign="top">â†‘indicates increase.<br><span class="Sup">a</span>Only if other drugs are not available and if clearly indicated. If treatment with life-sustaining drugs that cause pancreatic toxicity is required, suspension of didanosine is recommended (see <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a>, <a href="#i4i_section_id_631d91a4-0d32-4b91-a6ab-cdcc7123b236"> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a>).<br><span class="Sup">b</span>See <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>, <a href="#i4i_section_id_575a865e-36d3-4ecd-898f-1b1103274e75"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></a>.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3444d4b-a940-48fb-8c27-bf0423be2554"></a><a name="section-7.8"></a><p></p>
<h2>Nucleoside/nucleoside analogues:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9176c7c8-8251-4325-97a7-b2eadcffab21"></a><a name="section-7.8.1"></a><p></p>
<h3>Tenofovir disoproxil fumarate: </h3>
<p class="First">Exposure to didanosine is increase when coadministered with tenofovir (see <a href="#id_e0e9e975-8ccd-459c-a200-876e00d5b0cd">Table 3</a>, <a href="#id_29417304-bcff-441c-9751-0ac37671a977">5</a>, and <a href="#id_07c938a8-f6f0-4f2a-b348-49271d77d470">8</a>.) <span class="Bold">Inccreased exposure may cause or worsen didanosine-related clinical toxicities, including <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>,, symptomatic hyperlactatemia/<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. Coadministered of tenofovir with didanosine should be undertaken with caution, and </span><span class="Bold">patients should be monitored closely for didanosine-related toxicities. Didanosine sholuld be suspended if signs or symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, symptomatic hyperlactemia, or <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> develop (see <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a></span>).Administration of reduced doses of didanosine with tenofovir and a light meal resulted in didanosine exposures (AUC) similar to the recommended doese of didanosine given alone in the fasted state (see <a href="#id_e0e9e975-8ccd-459c-a200-876e00d5b0cd">Table 3</a>). Therefore, when administered with tenofovir, a dose reduction of didanosine to 250 mg (adults weighing â‰¥60 kg with creatinine clearance â‰¥60 mL/min) or 200 mg (adults weighing &lt;60 kg with creatinine clearance â‰¥60mL/min) once daily is recommended, and both drugs may be taken together with a light meal (â‰¤400 kcalories, â‰¤20% fat) or in the fasted state (see <a href="#i4i_dosage_admin_id_055d46aa-31c2-4214-b1b8-3001c48e832d">DOSAGE AND ADMINISTRATION</a>). Coadministration of didanosine with food decreases didanosine concentrations. Thus, although not studied, it is possible that coadministration with heavier meals could reduce didanosine concentrations further. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7eb2a76c-60db-4415-8d01-87d5ebb65c1c"></a><a name="section-7.8.2"></a><p></p>
<h3>Ribavirin:</h3>
<p class="First">Exposure to the active metabolite of didanosine (dideoxyadenosine 5'-triphosphate) is increased when didanosine is coadninstered  with ribavirin (see <a href="#id_fd1a7a28-da3c-4b56-a6ce-7581f537a42f">Table 9</a>). Fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, as well as <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and symptomatic hyperlactatemia/<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> have been reported in patients receiving both didanosine and ribavirin. Coadministration of didanosine and ribavirin is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ec839293-2bd5-42d2-b39c-4a9090242213"></a><a name="section-7.9"></a><p></p>
<h2>Carcinogenesis and Mutagenesis:</h2>
<p class="First">Lifetime carcinogenicity studies were conducted in mice and rats for 22 and 24 months, respectively. In the mouse study, initial doses of 120, 800, and 1200 mg/kg/day for each sex were lowered after 8 months to 120, 210, and 210 mg/kg/day for females and 120, 300, and 600 mg/kg/day for males. The two higher doses exceeded the maximally tolerated dose in females and the high dose exceeded the maximally tolerated dose in males. The low dose in females represented 0.68-fold maximum human exposure and the intermediate dose in males represented 1.7-fold maximum human exposure based on relative AUC comparisons. In the rat study, initial doses were 100, 250, and 1000 mg/kg/day, and the high dose was lowered to 500 mg/kg/day after 18 months. The upper dose in male and female rats represented 3-fold maximum human exposure. </p>
<p>Didanosine induced no significant increase in neoplastic lesions in mice or rats at maximally tolerated doses. </p>
<p>Didanosine was positive in the following genetic toxicology assays: 1) the Escherichia coli tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> WP2 uvrA bacterial mutagenicity assay; 2) the L5178Y/TK+/- mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> mammalian cell gene mutation assay; 3) the in vitro chromosomal aberrations assay in cultured human peripheral <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>; 4) the in vitro chromosomal aberrations assay in Chinese Hamster Lung cells; and 5) the BALB/c 3T3 in vitro transformation assay. No evidence of mutagenicity was observed in an Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> bacterial mutagenicity assay or in rat and mouse in vivo micronucleus assays. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_5fd36593-abaf-4ff2-ae51-81324b02d10b"></a><a name="section-7.10"></a><p></p>
<h2>Pregnancy, Reproduction and Fertility</h2>
<p class="First">Pregnancy Category B </p>
<p>Reproduction studies have been performed in rats and rabbits at doses up to 12 and 14.2 times the estimated human exposure (based upon plasma levels), respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to didanosine. At approximately 12 times the estimated human exposure, didanosine was slightly toxic to female rats and their pups during mid and late lactation. These rats showed reduced food intake and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gains</span> but the physical and functional development of the offspring was not impaired and there were no major changes in the F2 generation. A study in rats showed that didanosine and/or its metabolites are transferred to the fetus through the placenta. Animal reproduction studies are not always predictive of human response. </p>
<p>There are no adequate and well-controlled studies of didanosine in pregnant women. Didanosine should be used during pregnancy only if the potential benefit justifies the potential risk.</p>
<p>Fatal <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents. It is unclear if pregnancy augments the risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>/<span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span> syndrome reported in nonpregnant individuals receiving nucleoside analogues (see <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a>, <a href="#i4i_section_id_bb9c0477-3117-412d-9c84-62e9b8d292a8">2. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis:</a>). The combination of didanosine and stavudine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk. Healthcare providers caring for HIV-infected pregnant women receiving didanosine should be alert for early diagnosis of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>/<span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span> syndrome.</p>
<p>Antiretroviral Pregnancy Registry </p>
<p>To monitor maternal-fetal outcomes of pregnant women exposed to didanosine and other antiretroviral agents, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_46b90313-8a6f-45b7-b1c7-1fbd9c64363d"></a><a name="section-7.11"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV. A study in rats showed that following oral administration, didanosine and/or its metabolites were excreted into the milk of lactating rats. It is not known if didanosine is excreted in human milk. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breast-feed if they are receiving didanosine. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_f23ae835-2e0b-4116-8dcf-f24d3ca13b5c"></a><a name="section-7.12"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">The safety and efficacy of didanosine delayed-release capsules in pediatric patients have not been established. Please consult the complete prescribing information for didanosine chewable/dispersible buffered tablets and pediatric powder for oral solution for dosage and administration of didanosine to pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_672e0093-19ed-4ea4-842f-1ba71b3423b5"></a><a name="section-7.13"></a><p></p>
<h2>Geriatric use</h2>
<p class="First">In an Expanded Access Program using a buffered formulation of didanosine for the treatment of advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, patients aged 65 years and older had a higher frequency of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (10%) than younger patients (5%) (see <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a>). Clinical studies of didanosine, including those for didanosine delayed-release capsules, did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently than younger subjects. Didanosine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. In addition, renal function should be monitored and dosage adjustments should be made accordingly (see <a href="http://C:%5CDocuments%20and%20Settings%5Cmryman%5CLocal%20Settings%5CTemp%5C22e2ca82-c7b5-4f03-9a81-81e130237565.xml"></a><a href="#i4i_dosage_admin_id_055d46aa-31c2-4214-b1b8-3001c48e832d">DOSAGE AND ADMINISTRATION</a>, <a href="#i4i_section_id_ef3a13be-a6d6-4e0c-845a-bb47078dbe50">Dose Adjustment</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_ed8c3f9a-4fe6-4ad2-85f6-7e38d77f0406"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">A SERIOUS TOXICITY OF DIDANOSINE IS <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">PANCREATITIS</span>, WHICH MAY BE FATAL (see <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a>). OTHER IMPORTANT TOXICITIES INCLUDE <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS. RETINAL CHANGES AND <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">OPTIC NEURITIS</span>; AND <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">PERIPHERAL NEUROPATHY</span> (see <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a> and <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>).</p>
<p>When didanosine is used in combination with other agents with similar toxicities, the incidence of these toxicities may be higher than when didanosine is used alone. Thus, patients treated with didanosine in combination with stavudine, with or without hydroxyurea, may be at increased risk for <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (see <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>).</p>
<p>Selected clinical adverse events that occurred in a study of didanosine in combination with other antiretroviral agents are provided in <a href="#id_fcf53190-7914-4b90-afba-899cf23ce5c3">Table 10</a>.</p>
<a name="id_fcf53190-7914-4b90-afba-899cf23ce5c3"></a><table width="400">
<caption><span>Table 10: Selected Clinical Adverse Events, Study AI454-152<span class="Sup">a</span></span></caption>
<col width="61.8%">
<col width="20.5%">
<col width="17.8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="top">Percent of Patients<span class="Sup">b</span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Adverse Events</td>
<td class="Botrule Rrule" align="left" valign="top">didanosine+ stavudine+ nelfinavir n=258</td>
<td class="Botrule Lrule" align="left" valign="top">zidovudine/<br>lamivudine<span class="Sup">c</span>+ nelfinavir n=253</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Rrule" align="left" valign="top">57</td>
<td class="Botrule Lrule" align="left" valign="top">58</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Peripheral <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span>/<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></td>
<td class="Botrule Rrule" align="left" valign="top">25</td>
<td class="Botrule Lrule" align="left" valign="top">11</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="left" valign="top">24</td>
<td class="Botrule Lrule" align="left" valign="top">36</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="left" valign="top">22</td>
<td class="Botrule Lrule" align="left" valign="top">17</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Rrule" align="left" valign="top">14</td>
<td class="Botrule Lrule" align="left" valign="top">12</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Rrule" align="left" valign="top">14</td>
<td class="Botrule Lrule" align="left" valign="top">19</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> (see <a href="#i4i_section_id_a9c0e0db-d6ff-4253-9802-bb92120ab704">below</a>)</td>
<td class="Botrule Rrule" align="left" valign="top">&lt;1</td>
<td class="Botrule Lrule" align="left" valign="top">*</td>
</tr>
<tr class="Last"><td class="Botrule" align="left" colspan="3" valign="top">
<span class="Sup">a</span>Median duration of treatment was 62 weeks in the didansoine+stavudine+nelfinavir group and 61 weeks in the zidovudine/lamivudine+nelfinavir group.<br><span class="Sup">b</span>Percentages based on treated patients.<br><span class="Sup">c</span>Zidovudine/lamivudine combination tablet.<br>*This event was not observed in this study arm.</td></tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a9c0e0db-d6ff-4253-9802-bb92120ab704"></a><a name="section-8.1"></a><p></p>
<h2>In clinical trials using a buffered formulation of didanosine, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was observed in one patient who received didanosine plus stavudine plus nelfinavir, one patient who received didanosine plus stavudine plus indinavir, and 2 of 68 patietns who received didanosine plus stavudine plus indinavir plus hydroxyurea. In an early access program, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was observed in one patient who received didanosine plus stavudine plus hydroxyurea plus ritonavir plus indinavir plus efavirenz (see WARNINGS).</h2>
<p class="First">The frequency of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is dose related. In phase 3 studies with buffered formulations of didanosine, incidence ranged from 1% to 10% with doses higher than are currently recommended and 1% to 7% with recommended dose. Selected laboratory abnormalities that occurred in a study of didanosine in combination with other antiretroviral agents are shown in <a href="#id_cd6e38cb-80bb-4363-a929-47975fdc97f5">Table 11</a>.</p>
<a name="id_cd6e38cb-80bb-4363-a929-47975fdc97f5"></a><table width="0.000">
<caption><span>Table 11: Selected Laboratory Abnormalities, Study AI454-152<span class="Sup">a</span></span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Lrule" align="left" colspan="4" valign="top">Percent of Patients<span class="Sup">b</span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">
<p class="First">didanosine+ stavudine+ nelfinavir</p>
<p>n=258</p>
</td>
<td class="Botrule Lrule" align="left" colspan="2" valign="top">zidovudine/lamivudine<span class="Sup">c</span>+ nelfinavir n=253</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Parameter</td>
<td class="Botrule Rrule" align="left" valign="top">Grades 3 to 4<span class="Sup">d</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">All Grades</td>
<td class="Botrule Rrule" align="left" valign="top">Grades 3 to 4<span class="Sup">d</span>
</td>
<td class="Botrule Lrule" align="left" valign="top">All Grades</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (AST)</td>
<td class="Botrule Rrule" align="left" valign="top">5</td>
<td class="Botrule Rrule" align="left" valign="top">46</td>
<td class="Botrule Rrule" align="left" valign="top">5</td>
<td class="Botrule Lrule" align="left" valign="top">19</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">SGPT (ALT)</td>
<td class="Botrule Rrule" align="left" valign="top">6</td>
<td class="Botrule Rrule" align="left" valign="top">44</td>
<td class="Botrule Rrule" align="left" valign="top">5</td>
<td class="Botrule Lrule" align="left" valign="top">22</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Lipase</td>
<td class="Botrule Rrule" align="left" valign="top">5</td>
<td class="Botrule Rrule" align="left" valign="top">23</td>
<td class="Botrule Rrule" align="left" valign="top">2</td>
<td class="Botrule Lrule" align="left" valign="top">13</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Bilirubin</td>
<td class="Botrule Rrule" align="left" valign="top">&lt;1</td>
<td class="Botrule Rrule" align="left" valign="top">9</td>
<td class="Botrule Rrule" align="left" valign="top">&lt;1</td>
<td class="Botrule Lrule" align="left" valign="top">3</td>
</tr>
<tr class="Last"><td class="Botrule" align="left" colspan="5" valign="top">
<p class="First"><span class="Sup">a</span>Median duration of treatment was 62 weeks in the didanosine+stavudine+nelfinavir group and 61 weeks in the zidovudine/lamivudine+nelfinavir group.</p>
<p><span class="Sup">b</span>Percentages based on treated patients.</p>
<p><span class="Sup">c</span>Zidovudine/lamivudine combination tablet.</p>
<p><span class="Sup">d</span>&gt;5 x ULN for <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> and SGPT, â‰¥2.1 x ULN for lipase, and â‰¥2.6 x ULN for bilirubin (ULN = upper limit of normal).</p>
</td></tr>
</tbody>
</table>
<p>Observed During Clinical Practice:</p>
<p>The following events have been identified during postapproval use of didanosine beffered formulations. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to their seriousness, frequency of reporting, causal connection to didanosine, or a combination of these factors. </p>
<p>Body as a Whole: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and redistribution/accumulation of body fat (see <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>, <a href="#i4i_section_id_20df593d-a4cd-4266-accb-33217129e470">Fat Redistribution</a>).</p>
<p>Digestive Disorders: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>.</p>
<p>Exocrine Gland Disorders: <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (including fatal cases) (see <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a>), <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialoadenitis</span>, <span class="product-label-link" type="condition" conceptid="4106572" conceptname="Hypertrophy of parotid gland">parotid gland enlargement</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>.</p>
<p>Hematologic Disorders: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p>Liver: symptomatic hyperlactatemia/<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span> (see <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a>); <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">Metabolic Disorders</span>: diabete melitus, elevated serum alkaline phosphatase level, elevated serum amylase level, elevated serum gamma-glutamyltransferase level, elevated serum uric acid level, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span>: <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (with or without increases in creatinine kinase), <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and hemodialysis, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>.</p>
<p>Ophthalmologic Disorders: <span class="product-label-link" type="condition" conceptid="4318984" conceptname="Retinal depigmentation">retinal depigmentation</span> and <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> (see <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_5c330702-4091-49ae-9451-9a53079c5a12"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There is no known antidote for didanosine overdosage. In phase 1 studies, in which buffered formulations of didanosine were initially administered at doses ten times the currently recommended dose, toxicities included: <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, and hepatic dysfunction. Didanosine is not dialyzable by peritoneal dialysis, although there is some clearance by hemodialysis (see <a href="http://C:%5CDocuments%20and%20Settings%5Cmryman%5CLocal%20Settings%5CTemp%5C22e2ca82-c7b5-4f03-9a81-81e130237565.xml"></a><a href="#i4i_clinical_pharmacology_id_1e56d9b2-8fa8-4b79-9eb4-d952e63580b2">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_section_id_b7e4c5d4-a8f6-46df-a8f7-6f731505b34d">Pharmacokinetics</a>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_055d46aa-31c2-4214-b1b8-3001c48e832d"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf33f3dd-769b-49a4-8fcf-6c2d1cfc8846"></a><a name="section-10.1"></a><p></p>
<h2>Adults:</h2>
<p class="First">Didanosine should be administered on an empty stomach. Didanosine delayed-release capsules should be swallowed intact.</p>
<p>The recommended daily dose is dependent on body weight and is adminstered as one capsule given on a once-daily schedule as outlined in <a href="#id_2c6e4865-ec7f-4f62-a0de-e878596db4c0">Table 12</a>.</p>
<a name="id_2c6e4865-ec7f-4f62-a0de-e878596db4c0"></a><table width="0.000">
<caption><span>Table 12: Dosing of Didanosine Delayed-Release Capsules</span></caption>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="top">Patient Weight</td>
<td class="Botrule Lrule" align="left" valign="top">Dosage</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">â‰¥60 kg</td>
<td class="Botrule Lrule" align="left" valign="top">400 mg once daily</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top">&lt;60 kg</td>
<td class="Botrule" align="left" valign="top">250 mg once daily</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e2cc3052-edcd-4ffd-bd6f-fdff4ea523db"></a><a name="section-10.2"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">Didanosine delayed-release capsules have not been studied in pediatric patients. Please consult the complete prescribing information for didanosine chewable/dispersible buffered tablets and pediatric powder for oral solution for dosage and administration of didanosine to pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ef3a13be-a6d6-4e0c-845a-bb47078dbe50"></a><a name="section-10.3"></a><p></p>
<h2>Dose Adjustment:</h2>
<p class="First">Clinical and laboratory signs suggestive of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> should prompt dose suspension and careful evaluation of the possibility of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Didanosine use should be discontinued in patients with confirmed <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (see <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a> and <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>, <a href="#i4i_drug_interaction_id_1c08786b-8f64-4c54-88b2-6a989b6792c4">Drug Interactions</a></p>
<p>). Based on data with buffered didanosine formulations, patients with symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> may tolerate a reduced dose of didanosine after resolution of the symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> upon drug interruption. If <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> recurs after resumption of didanosine, permanent discontinuation of didanosine should be considered.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e8c94d8d-d6af-482c-9699-47133b79ee5a"></a><a name="section-10.3.1"></a><p></p>
<h3>Concomitant Therapy:</h3>
<p class="First">Tenofovir disoproxil fumarate. A dose reduction of didanosine delayed-release capsules to 250 mg (adults weighing â‰¥60 kg with creatinine clearance â‰¥60 mL/min) or 200 mg (adults weighing â‰¥60 kg with creatinine clearance â‰¥60 mL/min) once taken daily together with tenofovir and a light meal (â‰¤400 kcalories, â‰¤20% fat) or in the fasted state is recommended. The appropriate dose of didanosine delayed-release capsules coadministered with tenofovir in patients with creatinine clearance &lt;60 mL/min has not been established. (See <a href="#i4i_clinical_pharmacology_id_1e56d9b2-8fa8-4b79-9eb4-d952e63580b2">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_drug_interaction_id_1c08786b-8f64-4c54-88b2-6a989b6792c4">Drug Interactions</a> and <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>, <a href="#i4i_section_id_d91d9f86-90ea-4ab6-b400-745b349d7afa">Drug Interactions</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ef4e4f0e-e1aa-45a7-bc1f-a513ca9db890"></a><a name="section-10.3.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</h3>
<p class="First">Dosing recommendations for didanosine delayed-release capsules and didanosine buffered formulations are different for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Please consult the complete prescribing information on administration of didanosine buffered formulations to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In adult patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, the dose of didanosine should be adjusted to compensate for the slower rate of elimination. The recommended doses and dosing intervals of didanosine in adult patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> are presented in Table 13.</p>
<a name="id_a81db937-8729-4565-9f89-9df6bddd8f84"></a><table width="431">
<caption><span>Table 13: Recommended Dosage of Didanosine in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> by Body Weight<span class="Sup">a</span></span></caption>
<col width="54.8%">
<col width="25.5%">
<col width="19.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="top">Dosage (mg)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Creatinine Clearance (mL/min)</td>
<td class="Botrule Rrule" align="left" valign="top">â‰¥ 60 kg</td>
<td class="Botrule Lrule" align="left" valign="top">&lt; 60 kg</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">60</td>
<td class="Botrule Rrule" align="left" valign="top">400 once daily</td>
<td class="Botrule Lrule" align="left" valign="top">250 once daily</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">30 to 59</td>
<td class="Botrule Rrule" align="left" valign="top">200 once daily</td>
<td class="Botrule Lrule" align="left" valign="top">125 once daily</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">10 to 29</td>
<td class="Botrule Rrule" align="left" valign="top">125 once daily</td>
<td class="Botrule Lrule" align="left" valign="top">125 once daily</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">&lt;10</td>
<td class="Botrule Rrule" align="left" valign="top">125 once ddaily</td>
<td class="Botrule Lrule" align="left" valign="top"><span class="Sup">b</span></td>
</tr>
<tr class="Last"><td class="Botrule" align="left" colspan="3" valign="top">
<p class="First"><span class="Sup">a</span>Based on studies using a buffered formulation of didanosine</p>
<p><span class="Sup">b</span>Not suitable for use in patients &lt;60 kg with CLCR &lt;10 mL/min. An alternate formulation of didanosine should be used.</p>
</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_059fe846-4ea2-44b3-8e33-eba6910b54f4"></a><a name="section-10.3.3"></a><p></p>
<h3>Patients Requiring Continuous Ambulatory Peritoneal Dialysis (CAPD) or Hemodialysis:</h3>
<p class="First">For patients requiring CAPD or hemodialysis, follow dosing recommendations for patients with creatinine clearance less than 10 mL/min, shown in <a href="#id_a81db937-8729-4565-9f89-9df6bddd8f84">Table 13</a>. It is not necessary to administer a supplement dose of didanosine following hemodialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e0ca4e19-08d8-4162-8ba6-b4200969a292"></a><a name="section-10.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: </h2>
<p class="First">(See <a href="#i4i_warnings_id_a4402056-2e06-4bec-8d7c-d7b091ce3279">WARNINGS</a> and <a href="#i4i_precautions_id_9ff578e1-6861-4373-812e-4d66e53361e4">PRECAUTIONS</a>.) </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_5556acfa-1c7b-477e-88e7-6e47516348ea"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Didanosine Delayed-Release Capsules are available as:</p>
<p>250 mg: Two-piece hard gelatin capsule with blue opaque cap and white opaque body filled with white pellets. Imprinted in black ink stylized barr 589 over 250 mg. Available in unit dose packages of 30 (3x10) NDC 62584-046-21</p>
<p>400 mg: Two-piece hard gelatin capsule with red opaque cap and white opaque body filled with white pellets. Imprinted in black ink stylized barr 590 over 400 mg. Available in unit dose packages of 30 (3x10) NDC 62584-048-21.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dff5a2f6-a52d-4989-9e48-d1ec4f0d3f1f"></a><a name="section-11.1"></a><p></p>
<h2>HANDLING AND DISPOSAL:</h2>
<p class="First">Disposal options include incineration, landfill, or sewer as dictated by specific circumstances and relevant national, state, and local regulations.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_52abbc3f-d3ad-4036-8399-176e0c66042f"></a><a name="section-11.2"></a><p></p>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_8328d9d4-966b-4452-ba22-ff062f7d9b09"></a><a name="section-12"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p><span class="Bold">Didanosine Delayed-Release Capsules Enteric-Coated Pellets</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fb1180ed-ead7-4385-a6f9-543fcd28e201"></a><a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">What is didanosine?</span><br>
</h2>
<p class="First">Didanosine is a prescription medicine used in combination with other drugs to treat children and adults who are infected with HIV (the human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus, the virus that causes AIDS). Didanosine belongs to a class of drugs called nucleoside analogues. By reducing the growth of HIV, didanosine helps your body maintain its supply of CD4 cells, which are important for fighting HIV and other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </p>
<p>Didanosine will not cure your <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. At present there is no cure for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. Even while taking didanosine, you may continue to have HIV-related illnesses, including <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with other disease-producing organisms. Continue to see your doctor regularly and report any medical problems that occur. </p>
<p>Didanosine does not prevent a patient infected with HIV from passing the virus to other people. To protect others, you must continue to practice safe sex and take precautions to prevent others from coming in contact with your blood and other body fluids. </p>
<p>There is limited information on the antiviral response of long-term use of didanosine. </p>
<p>In didanosine, an enteric coating is used to protect the medicine while it is in your stomach since stomach acids can break it down. The enteric coating dissolves when the medicine reaches your small intestine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c1e570aa-265b-4340-bca8-456556782b4e"></a><a name="section-12.2"></a><p></p>
<h2><span class="Bold">Who should not take didanosine?<br></span></h2>
<p class="First">Do not take didanosine if you are allergic to any of its ingredients, including its active ingredient, didanosine, and the inactive ingredients. (See Inactive Ingredients at the end of this leaflet.) Tell your doctor if you think you have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to any of these ingredients. Because it has only been studied in adults, didanosine is not recommended for children. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de2c46c2-1064-45f9-8a3d-cfc644f26789"></a><a name="section-12.3"></a><p></p>
<h2><span class="Bold">How should I take didanosine?/How should I store it?<br></span></h2>
<p class="First">Didanosine should only be taken once daily. Your doctor will determine your dose based on your body weight, kidney and liver function, other medicines you are taking, and any side effects that you may have had with didanosine or other medicines. <span class="Bold">Take didanosine on an empty stomach. Do not take didanosine with food.</span> Swallow the capsule whole; do not open it. Try not to miss a dose, but if you do, take it as soon as possible. If it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. </p>
<p>Store capsules in a tightly closed container at room temperature away from heat and out of the reach of children and pets. </p>
<p><span class="Bold">If you have kidney disease:</span> If your kidneys are not working properly, your doctor will need to do regular tests to check how they are working while you take didanosine. Your doctor may also lower your dosage of didanosine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ac1973e-aeb0-4a97-b426-f2c026349d5b"></a><a name="section-12.4"></a><p></p>
<h2><span class="Bold">What should I do if someone takes an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of didanosine?</span></h2>
<p class="First">If someone may have taken an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of didanosine, get medical help right away. Contact their doctor or a poison control center. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_429bef7b-d614-42bc-9cfc-9f51b86fe49a"></a><a name="section-12.5"></a><p></p>
<h2><span class="Bold">What should I avoid while taking didanosine?</span></h2>
<p class="First"><span class="Bold">Alcohol.</span> Do not drink alcohol while taking didanosine since alcohol may increase your risk of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas) or <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>.</p>
<p><span class="Bold">Other medicines</span>. Other medicines, including those you can buy without a prescription, may interfere with the actions of didanosine or may increase the possibility or severity of side effects.  <span class="Bold">Do not take any medicine, vitamin supplement, or other health preparation without first checking with your doctor.</span></p>
<p><span class="Bold">Pregnancy.</span> It is not known if didanosine can harm a human fetus. Also, pregnant women have experienced serious side effects when taking didanosine in combination with ZERIT (stavudine), also known as d4T, and other HIV medicines. Didanosine should be used during pregnancy only after discussion with your doctor. <span class="Bold">Tell your doctor if you become pregnant or plan to become pregnant while taking didanosine.</span></p>
<p><span class="Bold">Nursing</span>. Studies have shown didanosine is in the breast milk of animals getting the drug. It may also be in human breast milk. The Centers for Disease Control and Prevention (CDC) recommends that HIV-infected mothers not breast-feed. This should reduce the risk of passing <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> to their babies and the potential for serious adverse reactions in nursing infants. Therefore, do not nurse a baby while taking didanosine.</p>
<p><span class="Bold">What are the possible side effects of didanosine?</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></span>. <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> is a dangerous <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas that may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="Bold">Tell your doctor right away if you or a child taking didanosine develop <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</span><span class="Bold">These can be signs of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</span> Before starting didanosine therapy, let your doctor know if you or a child for whom it has been prescribed have ever had <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. This condition is more likely to happen in people who have had it before. It is also more likely in people with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>. However, it can occur at any stage of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>. It may be more common in patients with kidney problems, those who drink alcohol, and those who are also treated with stavudine. If you get <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, your doctor will tell you to stop taking didanosine. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span>, severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span>,</span> and <span class="Bold"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>,</span> including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, have been reported among patients taking didanosine (including pregnant women). Symptoms that may indicate a liver problem are: </p>
<p>â€¢ feeling very weak, tired, or uncomfortable </p>
<p>â€¢ unusual or unexpected <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span> </p>
<p>â€¢ <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">feeling cold</span> </p>
<p>â€¢ feeling dizzy or lightheaded </p>
<p>â€¢ suddenly developing a slow or irregular heartbeat </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a medical emergency that must be treated in a hospital</span>. </p>
<p>If you notice any of these symptoms or if your medical condition changes, stop taking didanosine and call your doctor right away. Women, overweight patients, and those who have been treated for a long time with other medicines used to treat <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> are more likely to develop <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Your doctor should check your liver function periodically while you are taking didanosine. You should be especially careful if you have a history of heavy alcohol use or a liver problem. </p>
<p><span class="Bold">Vision changes</span>. Didanosine may affect the nerves in your eyes. Because of this, you should have regular eye examinations. You should also report any changes in vision to your doctor right away. This includes, for example, seeing colors abnormally or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span></span>. This is a problem with the nerves in your hands or feet. The nerve problem may be serious. <span class="Bold">Tell your doctor right away if you have continuing <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the feet or hands</span>.</p>
<p>Before starting didanosine therapy, let your doctor know if you have ever had <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. This condition is more likely to happen in people who have had it before. It is also more likely in patients taking medicines that affect the nerves and in people with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>. However, it can occur at any stage of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>. If you get <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, your doctor will tell you to stop taking didanosine. After stopping didanosine, the symptoms may get worse for a short time and then get better. Once symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> go away completely, you and your doctor should decide if starting didanosine again is right for you. If so, you might be started at a lower dose.</p>
<p><span class="Bold">Special note about other medicines</span>. If you take didanosine along with other medicines with similar side effects, you may increase the chance of having these side effects. For example, using didanosine in combination with other medicines that may cause <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, or liver problems (including stavudine) may increase your chance of having these side effects. </p>
<p><span class="Bold">Other side effects</span>: The most common side effects in adults taking didanosine in combination with other HIV drugs included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. </p>
<p>Changes in body fat have been seen in some patients taking antiretroviral therapy. These changes may include an increased amount of fat in the upper back and neck (â€œbuffalo humpâ€?), breast, and around the trunk. Loss of fat from the legs, arms, and face may also happen. The cause and long term health effects of these conditions are not known at this time. </p>
<p><span class="Bold">Inactive Ingredients:</span></p>
<p>Croscarmellose sodium, hydroxypropyl cellulose, hypromellose, methacrylic acid copolymer dispersion, microcrystalline cellulose, polydextrose, polyethylene glycol, silicon dioxide, sodium hydroxide, talc, titanium dioxide, triacetin and triethyl citrate. The capsule shell contains FD&amp;C blue no. 1, gelatin, and titanium dioxide. The 200 mg capsule shell also contains D&amp;C red no. 33, and FD&amp;C yellow no. 6. The 250 mg capsule shell also contains D&amp;C red no. 28. The 400 mg capsule shell also contains D&amp;C red no. 33, and FD&amp;C yellow no. 6. The edible imprinting ink contains D&amp;C yellow no. 10 aluminum lake, FD&amp;C blue no. 1 aluminum lake, FD&amp;C blue no. 2 aluminum lake, FD&amp;C red no. 40 aluminum lake, iron oxide, propylene glycol and shellac glaze.</p>
<p>This medicine was prescribed for your particular condition. Do not use didanosine for another condition or give it to others. Keep didanosine and all medicines out of the reach of children. w Throw away didanosine when it is outdated or no longer needed by <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> it down the toilet or pouring it down the sink. </p>
<p>This summary does not include everything there is to know about didanosine. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. If you have questions or concerns, or want more information about didanosine, your physician and pharmacist have the complete prescribing information upon which this leaflet is based. You may want to read it and discuss it with your doctor or other healthcare professional. Remember, no written summary can replace careful discussion with your doctor. </p>
<p>This Patient Information Leaflet has been approved by the U.S. Food and Drug Administration. </p>
<p>Zerit is a registered trademark of Bristol-Myers Squibb Company.</p>
<p>Manufactured by:<br>Barr Laboratories, Inc.<br>Pomona, NY 10970</p>
<p>Repackaged by<br>American Health Packaging<br>Columbus, Ohio 43217</p>
<p>8004621/0804</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_79379a3d-8f0d-4275-8a16-b6d8fa1ae93a"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Didanosine Delayed-Release Capsules (enteric-coated pellets) 250 mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79d6a5ea-77d3-4547-aa67-1b465141b1f5&amp;name=79d6a5ea-77d3-4547-aa67-1b465141b1f5-03.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d367a245-b157-49dc-be30-bf2bcc965d69"></a><a name="section-13.1"></a><p></p>
<h2>Label Text</h2>
<p class="First">NDC 62584-046-21</p>
<p><span class="Bold">Didanosine <br>Delayed-Release Capsules<br>(enteric-coated pellets)</span></p>
<p><span class="Bold">250 mg</span></p>
<p>30 Capsules (3x10)</p>
<p>Each capsule contains 250 mg of didanosine as<br>enteric-coated pellets.<br><span class="Bold">Usual Dosage:</span> See package insert.<br>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled<br>Room Temperature].<br><span class="Bold">Pharmacist:</span> Dispense the enclosed Patient <br>Information Leaflet with the drug product.</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Didanosine Delayed-Release Capsules (enteric-coated pellets) 400 mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=79d6a5ea-77d3-4547-aa67-1b465141b1f5&amp;name=79d6a5ea-77d3-4547-aa67-1b465141b1f5-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_05e9b50a-9783-4782-b51b-a7da9d4fa596"></a><a name="section-13.2"></a><p></p>
<h2>Label Text</h2>
<p class="First">NDC 62584-048-21</p>
<p><span class="Bold">Didanosine <br>Delayed-Release Capsules<br>(enteric-coated pellets)</span></p>
<p><span class="Bold">400 mg</span></p>
<p>30 Capsules (3x10)</p>
<p>Each capsule contains 400 mg of didanosine as<br>enteric-coated pellets.<br><span class="Bold">Usual Dosage:</span> See package insert.<br>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled<br>Room Temperature].<br><span class="Bold">Pharmacist:</span> Dispense the enclosed Patient <br>Information Leaflet with the drug product.</p>
<p><span class="Bold">Rx only</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIDANOSINEÂ 		
					</strong><br><span class="contentTableReg">didanosine capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:62584-046(NDC:0555-0589)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIDANOSINE</strong> (DIDANOSINE) </td>
<td class="formItem">DIDANOSINE</td>
<td class="formItem">250Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 28</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">barr;250mg;589</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62584-046-21</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62584-046-11</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077167</td>
<td class="formItem">12/08/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIDANOSINEÂ 		
					</strong><br><span class="contentTableReg">didanosine capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:62584-048(NDC:0555-0590)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIDANOSINE</strong> (DIDANOSINE) </td>
<td class="formItem">DIDANOSINE</td>
<td class="formItem">400Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 33</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">barr;400mg;590</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62584-048-21</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62584-048-11</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077167</td>
<td class="formItem">12/08/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>American Health Packaging
							(007914906)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>79d6a5ea-77d3-4547-aa67-1b465141b1f5</div>
<div>Set id: 79d6a5ea-77d3-4547-aa67-1b465141b1f5</div>
<div>Version: 1</div>
<div>Effective Time: 20091208</div>
</div>
</div>Â <div class="DistributorName">American Health Packaging</div></p>
</body></html>
